Recombinant Human Estradiol 17-Beta-Dehydrogenase 1 (HSD17B1) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-00593P
Greater than 85% as determined by SDS-PAGE.
Greater than 85% as determined by SDS-PAGE.

Recombinant Human Estradiol 17-Beta-Dehydrogenase 1 (HSD17B1) Protein (His&Myc)

Beta LifeScience SKU/CAT #: BLC-00593P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Product Overview

Description Recombinant Human Estradiol 17-Beta-Dehydrogenase 1 (HSD17B1) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity Greater than 85% as determined by SDS-PAGE.
Uniprotkb P14061
Target Symbol HSD17B1
Synonyms (17-beta-HSD 1)(20 alpha-hydroxysteroid dehydrogenase)(20-alpha-HSD)(E2DH)(Estradiol 17-beta-dehydrogenase 1)(Placental 17-beta-hydroxysteroid dehydrogenase)(Short chain dehydrogenase/reductase family 28C member 1)
Species Homo sapiens (Human)
Expression System E.coli
Tag N-10His&C-Myc
Target Protein Sequence ARTVVLITGCSSGIGLHLAVRLASDPSQSFKVYATLRDLKTQGRLWEAARALACPPGSLETLQLDVRDSKSVAAARERVTEGRVDVLVCNAGLGLLGPLEALGEDAVASVLDVNVVGTVRMLQAFLPDMKRRGSGRVLVTGSVGGLMGLPFNDVYCASKFALEGLCESLAVLLLPFGVHLSLIECGPVHTAFMEKVLGSPEEVLDRTDIHTFHRFYQYLAHSKQVFREAAQNPEEVAEVFLTALRAPKPTLRYFTTERFLPLLRMRLDDPSGSNYVTAMHREVFGDVPAKAEAGAEAGGGAGPGAEDEAGRGAVGDPELGDPPAAPQ
Expression Range 2-328aa
Protein Length Full Length of Mature Protein
Mol. Weight 42.3 kDa
Research Area Cancer
Form Liquid or Lyophilized powder
Buffer Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage 1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function Favors the reduction of estrogens and androgens. Converts estrone (E1) to a more potent estrogen, 17beta-estradiol (E2). Also has 20-alpha-HSD activity. Uses preferentially NADH.
Subcellular Location Cytoplasm.
Protein Families Short-chain dehydrogenases/reductases (SDR) family
Database References

Gene Functions References

  1. Our genetic study demonstrated HSD17B1 937 G variant as a risk factor for infertility in women with stage I and II endometriosis in Polish Caucasian patients. PMID: 28405865
  2. HSD17B1 is a promising marker to predict EC prognosis. PMID: 27923582
  3. Macronutrient intakes were associated with serum estradiol level, and these associations may be modified by HSD17B1 polymorphism in postmenopausal Japanese women. PMID: 28980890
  4. the effect of 17beta-HSD1 expression on breast cancer cell transcript profile in steroid-deprived condition, was investigated. PMID: 27544780
  5. Mutation in the 17-beta-hydroxysteroid dehydrogenase gene is associated with congenital adrenal hyperplasia. PMID: 28207417
  6. Substrate inhibition of 17beta-HSD1 in tumor epithelial cells and regulation of 17beta-HSD7 by 17beta-HSD1 knockdown has been demonstrated. PMID: 28554725
  7. 10 natural products were evaluated leading to inhibition of the activity of 17beta-HSD1 at the concentration of 25 muM, and six of them inhibit the activity over 50%. PMID: 27933483
  8. The structure of human 17beta-HSD1 and biological function have been studied extensively in the last two decades. In humans, the enzyme is expressed in placenta, ovary, endometrium and breast; high activity of estrogen activation provides the basis of 17beta-HSD1's implication in estrogen-dependent diseases, such as breast cancer, endometriosis and non-small cell lung carcinomas. [Review] PMID: 27102893
  9. These findings suggested that the HSD17B1 Ser312Gly polymorphism might confer genetic cancer susceptibility in an ethnic-dependent manner, especially among Caucasians. PMID: 26923943
  10. The rs605059 polymorphism of the HSD17B1 gene is associated with increased risk of recurrent spontaneous abortion. PMID: 25394609
  11. Review/Meta-analysis: HSD17B1 rs605059 polymorphisms were not associated with the risks of endometrial cancer or endometriosis. PMID: 26261478
  12. the HSD17B1 transcript and protein were identified in HeLa, SiHa, Ca Ski and C-33A cervical cancer cells. PMID: 26054693
  13. Increased expression of HSD17B1 in NSCLC may contribute to an elevated intratissue level of E2 and consequently may support the development and spread of cancer. PMID: 25564397
  14. The key enzymes of ovarian steroidogenesis, CYP 19 and 17beta-HSD, are active in the ovaries of postmenopausal women. PMID: 24855493
  15. 17beta-HSD1 and 17beta-HSD7 are principal reductive 17beta-hydroxysteroid dehydrogenases and major players in the viability of estrogen-dependent breast cancer cells. PMID: 25257817
  16. E1-induced ERELuc activity in the inhibitor-treated uterus was reduced by the HSD17B1 inhibitor. PMID: 25617485
  17. Single nucleotide polymorphism in HSD17B1 gene is associated with hepatocellular carcinoma. PMID: 24563232
  18. Onset of epileptiform discharges is modestly delayed in slices from ovariectomized rats replaced with physiologically relevant doses of EB, but the number of discharges is not affected. PMID: 24113171
  19. results demonstrated that HSD17B1 expression and its ability to convert the weak estrogen E1 to the more potent E2 can be associated with DNA methylation in the 5' flanking region in GC cells. PMID: 23916544
  20. analysis of intratumoral localization and activity of 17beta-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer PMID: 23837683
  21. We found the presence of HSD17B1 transcripts and proteins in human Jurkat acute T cell leukemia, Hut-78 and Raji B lymphoma cells PMID: 23540283
  22. HSD17B1-mediated decreased conversion of estrone to estradiol may reduce the estrogenic effects, thereby reducing the risk of developing breast cancer during long-term hormone replacement therapy use. [Meta-analysis] PMID: 23430226
  23. study demonstrated that 17beta-HSD1 increases breast cancer cell migration, in spite of its positive regulation of the antimetastatic gene NM23 PMID: 22691413
  24. In this review, the results suggest that HSD17B1 and PR polymorphism may play a role in the risk of endometriosis PMID: 22613790
  25. Frequencies of rs605059 AA genotype and A allele were significantly increased in Chinese patients with uterine leiomyoma compared to healthy controls. PMID: 22546946
  26. Data suggest that HSD17B1 is overexpressed in endometrial cancer tissue; HSD17B1 appears responsible for shift toward reductive metabolism (i.e., greater reduction of estrone to 17-beta-estradiol; lesser oxidation of 17-beta-estradiol to estrone). PMID: 22362820
  27. Breast cancer cells T47D, MCF-7, BT 20, and JEG 3 as control cells, were chosen to evaluate the contribution of 17beta-hydroxysteroid dehydrogenase type 1 and type 2 to the estradiol/estrone ratio. PMID: 22253796
  28. reduced HSD17B1 expression can be associated with DNA methylation in the 5' flanking region of HSD17B1 in CRC from the proximal colon. PMID: 22176788
  29. HSD17B1 gene may contribute to sex steroid-mediated effects on colorectal cancer development. PMID: 21317201
  30. SNPs (HSD17B1 (rs2010750, rs598126 and rs676387), COMT (rs4680), UGT1A1 (rs8175347) and ESR1 (rs9340799)) seem to be related to mammographic density in the same direction of their associations with breast cancer risk PMID: 22199302
  31. Data show that in 17beta-HSD1 inhibitors are placed in the substrate-binding site and they occupy an apolar subpocket consisting of the following amino acids: Gly94, Leu95, Leu96, Asn152, Tyr155, and Phe192. PMID: 21857977
  32. HSD17B1 upregulation by sodium butyrate is associated with increased conversion of E1 to E2 in colorectal cancer cells. PMID: 21563966
  33. Obese women with selected CYP19 and 17-beta HSD gene variants had remarkably different E2 trajectories around the the final menstrual period, resulting in different postmenopausal E2 levels. PMID: 21198743
  34. Genetic variants in ESR1, ESR2, and HSD17B1 genes could modify susceptibility to endometriosis and might influence the fertility status in endometriosis patients. PMID: 20586553
  35. This study suggests that HSD17B1 312Gly allele may be a protective factor for breast cancer development in Caucasians. PMID: 20151320
  36. CYP17 (T1931C) and HSD17beta1 (A1954G) polymorphisms may jointly increase the risk of breast cancer. PMID: 20193327
  37. genetic assiciation studies [Japan, Brazil]: data suggest SNP in 17beta-HSD1 gene may modify association between dietary isoflavone intake & breast cancer PMID: 20432167
  38. 17beta-HSD1 up-regulates breast cancer cell growth by a dual action on estradiol synthesis and dihydrotestosterone inactivation. PMID: 20172961
  39. A significant increment of 17beta-HSD1 followed exemestane neoadjuvant therapy of postmenopausal ER-positive breast carcinoma. This may represent the compensatory response of breast carcinoma tissues to estrogen depletion. PMID: 20151319
  40. An amino acid important for steroid/retinoid discrimination was identified and its significance was highlighted by the results of molecular modeling studies. PMID: 20382160
  41. Data report structures of the binary and ternary complexes of 17beta-HSD1 with a new inhibitor E2B, opening a new orientation of breast cancer treatment. PMID: 19929851
  42. increased activity in hypothalamic obesity PMID: 12519880
  43. possible hypothalamic mediators regulating adipose tissue 11 beta-HSD-1 might include down-regulation by CRH, ACTH, and alpha 2 sympathetic stimulation, and up-regulation by beta 2 sympathetic stimulation and by the cytokines TNFalpha and IL-1 beta PMID: 12519881
  44. examination of amplification in breast cancer PMID: 12527905
  45. Evidence for association between the Ser312Gly polymorphism in HSD17B1 and endometriosis was found in a Japanese population PMID: 15640252
  46. the germline variants in HSD17B1 characterized by htSNPs do not substantially influence the risk of prostate cancer in U.S. and European whites PMID: 16311626
  47. Corticotrophin-releasing hormone (CRH) increased whereas alpha-helical CRH decreased the mRNA levels of STS, CYP19A1, and HSD17B1, the key enzymes for estrogen synthesis. PMID: 16467490
  48. HSD17B1 is a multispecific enzyme. PMID: 16480815
  49. importance of 17HSD type 2 in breast cancer- & non-tumour breast cell lines; high or low expression affected oestradiol concentration significantly; response dependent on endogenous expression of 17HSD type 1 which seems to be dominant to 17HSD type 2 PMID: 16954436
  50. These results suggest that soy consumption may interact with polymorphisms in the 17beta-HSD1 gene in relation to endometrial cancer risk. PMID: 17301695

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

More from High-Quality Recombinant Proteins
Sale
Recombinant Human PARP2 Protein (N-GST & C-6xHis)
  • Molecule: PARP2;
  • Species: Human;
  • Expression system: Baculovirus;
  • Tag: N-terminal GST-tagged and C-terminal 6xHis-tagged;
  • Sequence: Full Length;
CAT#: BLC-11423P

Save $650
Sale
Greater than 85% as determined by SDS-PAGE.
Recombinant Human ACP3 Protein (C-10xHis)
  • Molecule: ACP3;
  • Species: Human;
  • Expression system: Baculovirus;
  • Tag: C-terminal 10xHis-tagged;
  • Sequence: Partial of Isoform 2;
CAT#: BLC-11438P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human MUSK Protein (TBD)
  • Molecule: MUSK;
  • Species: Human;
  • Expression system: in vitro E.coli expression system;
  • Tag: TBD;
  • Sequence: Partial;
CAT#: BLC-11435P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human SLC39A1 Protein (N-GST)
  • Molecule: SLC39A1;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: N-terminal GST-tagged;
  • Sequence: Cytoplasmic Domain;
CAT#: BLC-11425P

Save $650
Sale
Greater than 90% as determined by SDS-PAGE.
Recombinant Human TLR5 Protein (C-6xHis)
  • Molecule: TLR5;
  • Species: Human;
  • Expression system: E.coli;
  • Tag: C-terminal 6xHis-tagged;
  • Sequence: Partial;
CAT#: BLC-11405P

Save $650
Sale
Greater than 85% as determined by SDS-PAGE.
Recombinant Human GPR20 Protein (N-10xHis)
  • Molecule: GPR20;
  • Species: Human;
  • Expression system: in vitro E.coli expression system;
  • Tag: N-terminal 10xHis-tagged;
  • Sequence: Full Length;
CAT#: BLC-11447P

Save $650
Recently viewed